icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I)
 
 
  Reported by Jules Levin
AASLD 2015 Nov 13-17 san Francisco, CA
 
Tarik Asselah1, Tarek I Hassanein2, Roula B Qaqish3, Jordan J Feld4, Christophe Hezode5, Stefan Zeuzem6, Peter Ferenci7, Tami Pilot-Mati as3, Yao Yu3, Rebecca Redman3, Niloufar Mobashery3
1Centre de Recherche sur l'Infl ammati on, Inserm UMR 1149, Universite Paris Diderot, AP-HP Hopital Beaujon, Clichy, France; 2Southern California Liver Centers and Southern California Research Center, Coronado, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States;
4Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 5Henri Mondor University Hospital, AP-HP, Universite Paris-Est, Creteil, France; 6JW Goethe University, Frankfurt, Germany; 7Medical University Vienna, Vienna, Austria

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

AASLD14.gif

AASLD15.gif